Mizokami Daisuke, Kosuda Shigeru, Shiotani Akihiro, Kinoshita Fumio, Saotome Keiichi, Morozumi Kyouei
Nihon Jibiinkoka Gakkai Kaiho. 2014 May;117(5):673-80. doi: 10.3950/jibiinkoka.117.673.
The purpose of this study was to comparatively assess the diagnostic accuracy between 131I SPECT/CT and 131I whole-body scintigraphy (WBS) in differentiated thyroid carcinoma outpatients following radioablation.
a retrospective cohort study was performed in eleven patients with differentiated thyroid carcinoma (fourteen studies), who underwent both 131I WBS and 131I SPECT/CT, 7-10 days after administration of 1,110 MBq of 131I for radioablation, following a total thyroidectomy. A head and neck surgeon and two nuclear medicine specialists first interpreted the WBS images, followed by SPECT/CT images.
SPECT/CT led to accurate revisions of the first diagnoses in 13 of 24 cervical foci of 131I uptake on WBS. Out of the 5 distant lesions, which were diagnosed as metastases by WBS alone, 5 (100%) were found out to be benign lesions by SPECT/CT. Thus, WBS was prone to be false-positive both in detecting cervical node metastases (13/28, 46.4%) and distant metastases (5/17, 29.4%). Eventually, SPECT/CT after 131I radioablation altered postoperative patients' management in 42.8% of patients with thyroid carcinoma by upstaging or down-staging their disease.
SPECT/CT after 131I radioablation for differentiated thyroid cancer patients determines more accurately cervical lymph node metastasis, thyroid remnants and distant metastasis than does WBS alone. Both WBS and SPECT/CT after 131I radioablation are highly recommended for appropriate management of differentiated thyroid cancer patients who have undergone a total thyroidectomy.
本研究旨在比较131I SPECT/CT与131I全身闪烁扫描(WBS)对分化型甲状腺癌患者放射性消融术后门诊患者的诊断准确性。
对11例分化型甲状腺癌患者(共14项研究)进行回顾性队列研究,这些患者在接受全甲状腺切除术后,给予1110MBq的131I进行放射性消融,7-10天后接受了131I WBS和131I SPECT/CT检查。一名头颈外科医生和两名核医学专家首先解读WBS图像,然后解读SPECT/CT图像。
SPECT/CT对WBS上24个颈部131I摄取灶中的13个进行了准确的首次诊断修正。在仅通过WBS诊断为转移灶的5个远处病变中,SPECT/CT发现5个(100%)为良性病变。因此,WBS在检测颈部淋巴结转移(13/28,46.4%)和远处转移(5/17,29.4%)方面均容易出现假阳性。最终,131I放射性消融后的SPECT/CT改变了42.8%甲状腺癌患者的术后管理,通过上调或下调其疾病分期。
对于分化型甲状腺癌患者,131I放射性消融后的SPECT/CT比单独的WBS更准确地确定颈部淋巴结转移、甲状腺残余组织和远处转移。强烈建议对接受全甲状腺切除术的分化型甲状腺癌患者进行131I放射性消融后的WBS和SPECT/CT检查,以进行适当的管理。